Why B(-)other? About the Gap of Unknowns in ALL

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Jun 16

PMID 35708724

Authors

Thoas Fioretos

Affiliations

Soon will be listed here.

References

Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H . Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood. 2021; 139(12):1850-1862. DOI: 10.1182/blood.2021011921. View

Yang M, Safavi S, Woodward E, Duployez N, Olsson-Arvidsson L, Ungerback J . 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood. 2020; 136(8):946-956. PMC: 7498303. DOI: 10.1182/blood.2019004684. View

Passet M, Kim R, Gachet S, Sigaux F, Chaumeil J, Galland A . Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood. 2022; 139(24):3505-3518. PMC: 9203705. DOI: 10.1182/blood.2021014723. View

Kimura S, Mullighan C . Molecular markers in ALL: Clinical implications. Best Pract Res Clin Haematol. 2020; 33(3):101193. PMC: 7548398. DOI: 10.1016/j.beha.2020.101193. View

Umeda M, Ma J, Huang B, Hagiwara K, Westover T, Abdelhamed S . Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. Blood Cancer Discov. 2022; 3(3):194-207. PMC: 9780084. DOI: 10.1158/2643-3230.BCD-21-0160. View

Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta E . Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022; 139(24):3519-3531. PMC: 9203703. DOI: 10.1182/blood.2022015444. View

Vu T, Straube J, Porter A, Bywater M, Song A, Ling V . Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nat Commun. 2020; 11(1):3021. PMC: 7296000. DOI: 10.1038/s41467-020-16840-2. View

Gu Z, Churchman M, Roberts K, Moore I, Zhou X, Nakitandwe J . PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019; 51(2):296-307. PMC: 6525306. DOI: 10.1038/s41588-018-0315-5. View

Oh S, Shao J, Mitra J, Xiong F, DAntonio M, Wang R . Enhancer release and retargeting activates disease-susceptibility genes. Nature. 2021; 595(7869):735-740. PMC: 11171441. DOI: 10.1038/s41586-021-03577-1. View

10.

Lilljebjorn H, Fioretos T . New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 2017; 130(12):1395-1401. DOI: 10.1182/blood-2017-05-742643. View

11.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

12.

Belver L, Albero R, Ferrando A . Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. Trends Immunol. 2021; 42(5):418-431. PMC: 8091164. DOI: 10.1016/j.it.2021.03.005. View